Deal Details

Arcturus Completes $150 Million Follow-On Offering

Healthcare

Arcturus follow-on offering

Summary

Arcturus Therapeutics Holdings Inc. (“Arcturus”) (NASDAQ-GM:ARCT) recently completed an underwritten public offering of 1,365,000 shares of its common stock at a public offering price of $110.00 per share. The gross proceeds to Arcturus from the offering are expected to be approximately $150 million. In addition, Arcturus has granted the underwriters a 30-day option to purchase up to an additional 204,750 shares of common stock at the public offering price, less underwriting discounts and commissions.

Baird served as lead manager on this offering.

About

Arcturus is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, and Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (200 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. Arcturus Therapeutics Holdings Inc. is headquartered in San Diego, California.

Healthcare

Arcturus follow-on offering